NL8702403A - Oligopeptiden en gebruik daarvan voor diagnostische en vaccinatiedoeleinden voor aids en arc. - Google Patents
Oligopeptiden en gebruik daarvan voor diagnostische en vaccinatiedoeleinden voor aids en arc. Download PDFInfo
- Publication number
- NL8702403A NL8702403A NL8702403A NL8702403A NL8702403A NL 8702403 A NL8702403 A NL 8702403A NL 8702403 A NL8702403 A NL 8702403A NL 8702403 A NL8702403 A NL 8702403A NL 8702403 A NL8702403 A NL 8702403A
- Authority
- NL
- Netherlands
- Prior art keywords
- oligopeptides
- amino acid
- sequence
- aids
- amino acids
- Prior art date
Links
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 33
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 33
- 208000030507 AIDS Diseases 0.000 title claims abstract description 15
- 238000002255 vaccination Methods 0.000 title claims abstract description 7
- 150000001413 amino acids Chemical class 0.000 claims abstract description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 7
- 241000700605 Viruses Species 0.000 claims description 24
- 229960005486 vaccine Drugs 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 5
- 241000282577 Pan troglodytes Species 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 101710091045 Envelope protein Proteins 0.000 claims description 4
- 101710188315 Protein X Proteins 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 229940024606 amino acid Drugs 0.000 description 15
- 206010001513 AIDS related complex Diseases 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102100034349 Integrase Human genes 0.000 description 3
- 241000282579 Pan Species 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 241000714195 Aids-associated retrovirus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8702403A NL8702403A (nl) | 1987-10-09 | 1987-10-09 | Oligopeptiden en gebruik daarvan voor diagnostische en vaccinatiedoeleinden voor aids en arc. |
| CA000579498A CA1340914C (en) | 1987-10-09 | 1988-10-06 | Oligopeptides and their use for diagnostic and vaccination purposes for aids and arc |
| AU24896/88A AU623097B2 (en) | 1987-10-09 | 1988-10-07 | Oligopeptides and their use for diagnostic and vaccination purposes for aids and arc |
| JP63507895A JPH03501968A (ja) | 1987-10-09 | 1988-10-07 | オリゴペプチド、及びａｉｄｓまたはａｒｃの診断及びワクチン接種を目的としたそれらの用途 |
| EP88908398A EP0389489A1 (en) | 1987-10-09 | 1988-10-07 | Oligopeptides and their use for diagnostic and vaccination purposes for aids and arc |
| PCT/NL1988/000040 WO1989003391A1 (en) | 1987-10-09 | 1988-10-07 | Oligopeptides and their use for diagnostic and vaccination purposes for aids and arc |
| EP88202248A EP0311219B1 (en) | 1987-10-09 | 1988-10-07 | Oligopeptides and their use for diagnostic and vaccination purposes for AIDS and ARC |
| DE3855471T DE3855471T2 (de) | 1987-10-09 | 1988-10-07 | Oligopeptide und ihre Anwendung zu Diagnose- und Impfzwecken für AIDS und ARC |
| ES88202248T ES2094112T3 (es) | 1987-10-09 | 1988-10-07 | Oligopeptidos y su uso para el diagnostico y vacunacion relacionados con el sida y el crs. |
| AT88202248T ATE141287T1 (de) | 1987-10-09 | 1988-10-07 | Oligopeptide und ihre anwendung zu diagnose- und impfzwecken für aids und arc |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8702403A NL8702403A (nl) | 1987-10-09 | 1987-10-09 | Oligopeptiden en gebruik daarvan voor diagnostische en vaccinatiedoeleinden voor aids en arc. |
| NL8702403 | 1987-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8702403A true NL8702403A (nl) | 1989-05-01 |
Family
ID=19850727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8702403A NL8702403A (nl) | 1987-10-09 | 1987-10-09 | Oligopeptiden en gebruik daarvan voor diagnostische en vaccinatiedoeleinden voor aids en arc. |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP0311219B1 (ja) |
| JP (1) | JPH03501968A (ja) |
| AT (1) | ATE141287T1 (ja) |
| CA (1) | CA1340914C (ja) |
| DE (1) | DE3855471T2 (ja) |
| ES (1) | ES2094112T3 (ja) |
| NL (1) | NL8702403A (ja) |
| WO (1) | WO1989003391A1 (ja) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0328390B1 (en) * | 1988-02-10 | 1994-09-14 | Immulogic Pharmaceutical Corporation | Peptide treatment of refractory infectious diseases |
| CA1341285C (en) * | 1988-02-12 | 2001-08-14 | Chang Yi Wang | Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines |
| US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
| US5562905A (en) * | 1988-04-26 | 1996-10-08 | E. I. Du Pont De Nemours And Company | Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals |
| AU640619B2 (en) * | 1988-10-03 | 1993-09-02 | Repligen Corporation | Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids |
| SE9000333D0 (sv) * | 1990-01-31 | 1990-01-31 | Britta Wahren | Monoklonal antikropp |
| EP0448095A1 (en) * | 1990-03-21 | 1991-09-25 | Wolf, Hans Joachim, Prof. Dr. | Subregion of the retroviral ENV protein, DNA sequences encoding it and compositions for the diagnosis, prevention or therapy of retrovirus infections |
| AU8228791A (en) * | 1990-06-15 | 1992-01-07 | New York University | Heterohybridomas producing human monoclonal antibodies to hiv-1 |
| US5914109A (en) * | 1990-06-15 | 1999-06-22 | New York University | Heterohybridomas producing human monoclonal antibodies to HIV-1 |
| CA2047078A1 (en) * | 1990-07-19 | 1992-01-20 | Steven S. Bondy | Cyclic hiv principal neutralizing determinant peptides |
| CA2047031A1 (en) * | 1990-07-19 | 1992-01-20 | Stephen Marburg | Peptide-polysaccharide-protein conjugate vaccines |
| IL98845A0 (en) * | 1990-07-19 | 1992-07-15 | Merck & Co Inc | Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them |
| IL99077A0 (en) * | 1990-08-13 | 1992-07-15 | Merck & Co Inc | New embodiments of the hiv principal neutralizing determinant and pharmaceutical compositions containing them |
| US5627035A (en) * | 1990-08-22 | 1997-05-06 | Syntello Vaccine Development Ab | Peptides that block human immunodeficiency virus and methods of use thereof |
| AU667290B2 (en) * | 1990-08-22 | 1996-03-21 | Tripep Ab | Peptides that block human immunodeficiency virus infections and methods of use thereof |
| JPH06502539A (ja) * | 1990-10-26 | 1994-03-24 | ザ・パブリック・ヘルス・リサーチ・インスティチュート・オブ・ザ・シティ・オブ・ニューヨーク・インコーポレーテッド | Ｈｉｖ−１ ｇｐ１２０のｖ３ループおよびｃｄ−４結合部位に特異的な中和ヒトモノクローナル抗体 |
| EP0492920A1 (en) * | 1990-12-24 | 1992-07-01 | Merck & Co. Inc. | Chimaeric influenza-HIV vaccine |
| US6139843A (en) * | 1991-04-02 | 2000-10-31 | Albert Einstein College Of Medicine Of Yeshiva University | Peptide compositions for the treatment of HIV |
| JPH0570493A (ja) * | 1991-05-31 | 1993-03-23 | Chemo Sero Therapeut Res Inst | ヒト免疫不全ウイルス（ｈｉｖ）関連免疫調製物 |
| GB9318901D0 (en) * | 1993-09-13 | 1993-10-27 | Centre Nat Rech Scient | Multiple branch peptide construction |
| WO2009008888A1 (en) * | 2007-07-10 | 2009-01-15 | Matthias Rath | African swine virus polypeptides as vaccines and its therapeutic use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US779431A (en) * | 1903-06-02 | 1905-01-10 | American Tobacco Co | Cigarette-machine. |
| DE3588248T2 (de) * | 1984-10-18 | 2004-07-01 | Institut Pasteur | LAV-Antigene und -Peptide |
| WO1987002775A1 (en) * | 1985-10-24 | 1987-05-07 | Southwest Foundation For Biomedical Research | Synthetic peptides and use for diagnosis and vaccination for aids and arc |
-
1987
- 1987-10-09 NL NL8702403A patent/NL8702403A/nl not_active Application Discontinuation
-
1988
- 1988-10-06 CA CA000579498A patent/CA1340914C/en not_active Expired - Fee Related
- 1988-10-07 ES ES88202248T patent/ES2094112T3/es not_active Expired - Lifetime
- 1988-10-07 DE DE3855471T patent/DE3855471T2/de not_active Expired - Fee Related
- 1988-10-07 EP EP88202248A patent/EP0311219B1/en not_active Expired - Lifetime
- 1988-10-07 JP JP63507895A patent/JPH03501968A/ja active Pending
- 1988-10-07 AT AT88202248T patent/ATE141287T1/de active
- 1988-10-07 WO PCT/NL1988/000040 patent/WO1989003391A1/en not_active Application Discontinuation
- 1988-10-07 EP EP88908398A patent/EP0389489A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0311219B1 (en) | 1996-08-14 |
| EP0311219A1 (en) | 1989-04-12 |
| ATE141287T1 (de) | 1996-08-15 |
| JPH03501968A (ja) | 1991-05-09 |
| DE3855471T2 (de) | 1996-12-19 |
| CA1340914C (en) | 2000-02-29 |
| WO1989003391A1 (en) | 1989-04-20 |
| EP0389489A1 (en) | 1990-10-03 |
| DE3855471D1 (de) | 1996-09-19 |
| ES2094112T3 (es) | 1997-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL8702403A (nl) | Oligopeptiden en gebruik daarvan voor diagnostische en vaccinatiedoeleinden voor aids en arc. | |
| Gelderblom et al. | Morphogenesis and morphology of HIV structure-function relations | |
| Zwart et al. | Immunodominance and antigenic variation of the principal neutralization domain of HIV-1 | |
| Graham et al. | Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120: a randomized, double-blind trial | |
| Sasaki et al. | Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1 | |
| Girard et al. | Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1 | |
| Wang et al. | Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site | |
| ES2240526T3 (es) | Composicion farmaceutica para inmunizar contra el sida. | |
| EP0550599B1 (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
| LT3365B (en) | Vaccine for human immunodeficiency virus | |
| US20020183484A1 (en) | Immunogenic formulation and process for preparation thereof | |
| Ruprecht et al. | Vaccination with a live retrovirus: the nature of the protective immune response. | |
| Haffar et al. | HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles | |
| Girard et al. | Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus | |
| Montefiori et al. | Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus | |
| Zolla-Pazner et al. | Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope | |
| Browning et al. | Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies | |
| Levi et al. | Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1 | |
| US20050025779A1 (en) | HIV-1 envelope glycoproteins having unusual disulfide structure | |
| US20080267989A1 (en) | Hiv Gp-41-Membrane Proximal Region Arrayed On Hepatitis B Surface Antigen Particles as Novel Antigens | |
| EP0613378A1 (en) | Induction of protection against viral infection by synergy between viral proteins and viral peptides | |
| AU2002231510B2 (en) | Immunogenic formulations of variable peptidic epitopes and process for preparation thereof | |
| ES2631608T3 (es) | Variante de la glicoproteína Env del VIH-1 | |
| CA2057040A1 (en) | Induction of protection against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein | |
| Palker et al. | The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1B | A search report has been drawn up | ||
| BV | The patent application has lapsed |